Intravascular ultrasound (IVUS) developer Endosonics of Pleasanton,CA, has extended its product distribution relationship with Cordis.The deal gives Cordis, of Miami Lake, FL, exclusive distributionrights in North America and Europe to Endosonics IVUS
Intravascular ultrasound (IVUS) developer Endosonics of Pleasanton,CA, has extended its product distribution relationship with Cordis.The deal gives Cordis, of Miami Lake, FL, exclusive distributionrights in North America and Europe to Endosonics IVUS productsfor coronary applications. Cordis has agreed to provide fundingfor joint product development programs and made a $5 million equityinvestment in Endosonics.
Endosonics in January reported year-end financial results thatshowed revenues more than doubling, to $17.1 million from $8 millionin 1994. Its loss for the year narrowed, to $10.5 million comparedwith $13.3 million in 1994.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.